Nanna Witting

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2712686/publications.pdf

Version: 2024-02-01

58 papers	2,056 citations	279487 23 h-index	243296 44 g-index
58 all docs	58 docs citations	58 times ranked	2654 citing authors

#	Article	IF	Citations
1	Axial muscle involvement in patients with limb girdle muscular dystrophy type <scp>R9</scp>. Muscle and Nerve, 2022, 65, 405-414.	1.0	3
2	Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis. Journal of Neurology, 2022, 269, 4154-4160.	1.8	6
3	Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy. Oxford Medical Case Reports, 2021, 2021, omaa150.	0.2	6
4	Patients With Becker Muscular Dystrophy Have Severe Paraspinal Muscle Involvement. Frontiers in Neurology, 2021, 12, 613483.	1.1	2
5	Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?. Acta Neuropathologica Communications, 2021, 9, 109.	2.4	2
6	Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency. European Journal of Neurology, 2021, 28, 3121-3132.	1.7	13
7	Progression or Not â€“ A Small Natural History Study of Genetical Confirmed Congenital Myopathies. Journal of Neuromuscular Diseases, 2021, 8, 647-655.	1.1	1
8	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	1.0	11
9	Muscle biopsy and <scp>MRI</scp> findings in <scp>ANO5</scp>â€related myopathy. Muscle and Nerve, 2021, 64, 743-748.	1.0	6
10	Recurrent TTN metatranscriptâ€only c.39974â€“11T>G splice variant associated with autosomal recessive arthrogryposis multiplex congenita and myopathy. Human Mutation, 2020, 41, 403-411.	1.1	28
11	Responsiveness of outcome measures in myotonic dystrophy type 1. Annals of Clinical and Translational Neurology, 2020, 7, 1382-1391.	1.7	2
12	Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of Clinical and Translational Neurology, 2020, 7, 1327-1339.	1.7	16
13	Intrarater reliability and validity of outcome measures in myotonic dystrophy type 1. Neurology, 2020, 94, e2508-e2520.	1.5	7
14	Permanent muscle weakness in hypokalemic periodic paralysis. Neurology, 2020, 95, e342-e352.	1.5	17
15	Contractile properties are impaired in congenital myopathies. Neuromuscular Disorders, 2020, 30, 649-655.	0.3	2
16	Physical activity in myotonic dystrophy type 1. Journal of Neurology, 2020, 267, 1679-1686.	1.8	7
17	Quantitative Muscle MRI as Outcome Measure in Patients With Becker Muscular Dystrophyâ€”A 1-Year Follow-Up Study. Frontiers in Neurology, 2020, 11, 613489.	1.1	9
18	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.3	18

#	Article	IF	Citations
19	MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement. Acta Neuropathologica, 2019, 138, 1013-1031.	3.9	31
20	Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service. Journal of Neuromuscular Diseases, 2019, 6, 241-258.	1.1	32
21	Eculizumab improves fatigue in refractory generalized myasthenia gravis. Quality of Life Research, 2019, 28, 2247-2254.	1.5	32
22	Congenital myopathies are mainly associated with a mild cardiac phenotype. Journal of Neurology, 2019, 266, 1367-1375.	1.8	10
23	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	1.0	162
24	AB0652â€...QTC INTERVAL PROLONGATION IN A SCANDINAVIAN COHORT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES AND SYSTEMIC SCLEROSIS: CORRELATIONS WITH CLINICAL VARIABLES. , 2019, , .		0
25	FRI0320â€...CN-1A AUTOANTIBODIES ARE SPECIFIC FOR SPORADIC INCLUSION BODY MYOSITIS. , 2019, , .		0
26	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	2.8	93
27	Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. Acta Neurologica Scandinavica, 2018, 137, 452-461.	1.0	31
28	Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. Muscle and Nerve, 2018, 57, 1026-1030.	1.0	11
29	Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies â€“ Still a possible treatment modality?. Neuromuscular Disorders, 2018, 28, 914-926.	0.3	24
30	Altered somatosensory neurovascular response in patients with Becker muscular dystrophy. Brain and Behavior, 2018, 8, e00985.	1.0	1
31	Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark. Neurology: Genetics, 2017, 3, e140.	0.9	34
32	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	4.9	472
33	The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain, 2017, 140, 2295-2305.	3.7	49
34	Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. Neurotherapeutics, 2017, 14, 182-190.	2.1	14
35	Aerobic Training in Patients with Congenital Myopathy. PLoS ONE, 2016, 11, e0146036.	1.1	17
36	Prevalence and phenotypes of congenital myopathy due to Î±â€actin 1 gene mutations. Muscle and Nerve, 2016, 53, 388-393.	1.0	18

#	Article	IF	Citations
37	A heterozygous 21-bp deletion inCAPN3causes dominantly inherited limb girdle muscular dystrophy. Brain, 2016, 139, 2154-2163.	3.7	87
38	Axial myopathy: an overlooked feature of muscle diseases. Brain, 2016, 139, 13-22.	3.7	44
39	Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. Neurology, 2016, 86, 442-445.	1.5	51
40	Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years. Journal of Neuromuscular Diseases, 2015, 2, 167-174.	1.1	10
41	Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study. International Journal of Cardiology, 2015, 182, 403-411.	0.8	36
42	Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology, 2015, 84, 1772-1781.	1.5	50
43	Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient. Clinical Neurology and Neurosurgery, 2015, 130, 168-170.	0.6	5
44	Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurologica Scandinavica, 2014, 130, 125-130.	1.0	23
45	Severe Axial Myopathy in McArdle Disease. JAMA Neurology, 2014, 71, 88.	4.5	18
46	Pharmacologic Treatment of Downstream of Tyrosine Kinase 7 Congenital Myasthenic Syndrome. JAMA Neurology, 2014, 71, 350.	4.5	27
47	Effect of sildenafil on skeletal and cardiac muscle in <scp>B</scp>ecker muscular dystrophy. Annals of Neurology, 2014, 76, 550-557.	2.8	39
48	Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 59.	1.6	43
49	High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: A cross-sectional study. International Journal of Cardiology, 2014, 174, 31-36.	0.8	44
50	Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy. Neuromuscular Disorders, 2014, 24, 325-330.	0.3	17
51	Decreased Variability of the 6-Minute Walk Test by Heart Rate Correction in Patients with Neuromuscular Disease. PLoS ONE, 2014, 9, e114273.	1.1	24
52	Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. Journal of Neurology, 2013, 260, 2084-2093.	1.8	63
53	Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscular Disorders, 2013, 23, 25-28.	0.3	15
54	Response. Neuromuscular Disorders, 2013, 23, 193.	0.3	0

#	Article	IF	Citations
55	Cardiac manifestations of myotonic dystrophy type 1. International Journal of Cardiology, 2012, 160, 82-88.	0.8	146
56	Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. Acta Myologica, 2011, 30, 182-4.	1.5	5
57	A PET activation study of brush-evoked allodynia in patientswith nerve injury pain. Pain, 2006, 120, 145-154.	2.0	122
58	Effects of rhythmic auditory stimulation on walking during the 6-minute walk test in patients with generalised Myasthenia Gravis. European Journal of Physiotherapy, 0, , 1-000.	0.7	0